AQST
Aquestive Therapeutics missed third quarter 2026 revenue and EPS estimates while securing an Anaphylm PDUFA date
Aquestive Therapeutics reported a significant revenue decline in the third quarter of 2026, largely attributed to the timing of manufacturing orders for...
